Added to YB: 2026-05-13
Pitch date: 2026-03-02
VIR [bullish]
Vir Biotechnology, Inc.
+3.84%
current return
Author Info
No bio for this author
Company Info
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Market Cap
$1.5B
Pitch Price
$9.05
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.67
P/E
-2.90
EV/Sales
17.67
Sector
Biotechnology
Category
growth
Vir Biotechnology, Inc. - $VIR
VIR: Best-in-class TCE VIR-5500 for mCRPC w/ PRO-XTEN masking tech avoids CRS toxicity. Ph1 (n=58): 82% PSA50, 53% PSA90, 45% ORR, no dose-limiting toxicities vs Janux 26% PSA90. Astellas deal $1.7B total ($335M upfront, 50/50 US profit split, 60% dev costs). ~$950M cash vs $1.4B mcap = <$500M platform value. Q2 2026 expansion data catalyst; Ph3 2027, FDA approval 2029-30. Asymmetric to $2B+ on positive data or Astellas acquisition pre-launch.
Read full article (3 min)